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Abstract
Background: Sickle cell disease (SCD) is a devastating, multisystemic disorder that
affects millions of people worldwide. The earliest clinical manifestations of SCD can
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affect infants as young as 6 months of age, and pediatric patients are at risk for acute
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and life-threatening complications. Early intervention with treatments that target the
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underlying pathophysiological mechanism of SCD, sickle hemoglobin (HbS) polymerization, are expected to slow disease progression and circumvent disease-associated
morbidity and mortality.
Procedure: The HOPE-KIDS 1 trial (NCT02850406) is an ongoing four-part, phase
2a, open-label, single- and multiple-dose study to evaluate the pharmacokinetics,
efficacy, and safety of voxelotor—a first-in-class HbS polymerization inhibitor—in
patients aged 6 months to 17 years with SCD. Initial findings from a cohort of 45
patients aged 4 to 11 years who received voxelotor treatment for up to 48 weeks are
reported.
Results: Hemoglobin (Hb) response, defined as a >1.0 g/dl increase from baseline,
was achieved at week 24 by 47% (n = 16/34) of patients with Hb measurements at
baseline and week 24. At week 24, 35% (n = 12/34) and 21% (n = 7/34) of patients
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had a >1.5 g/dl increase and a >2.0 g/dl increase from baseline in Hb concentra-
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tion, respectively. Concurrent improvements in hemolytic markers were observed.
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Voxelotor was well tolerated in this young cohort, with no newly emerging safety
signals.
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Abbreviations: Hb, hemoglobin; HbS, sickle hemoglobin; HU, hydroxyurea; LDH, lactate dehydrogenase; PK, pharmacokinetics; SCD, sickle cell disease; TEAE, treatment-emergent adverse event;
VOC, vaso-occlusive crisis.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2022 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals LLC.
Pediatr Blood Cancer. 2022;69:e29716.
https://doi.org/10.1002/pbc.29716

wileyonlinelibrary.com/journal/pbc

1 of 10

2 of 10

ESTEPP ET AL .

Correspondence
Clark Brown, Emory + Children’s Pediatric
Institute, 5461 Meridian Mark RD NE, 4th
Floor MOB, Atlanta, GA 30342, USA.
Email: Clark.Brown@choa.org
Paper was presented at the virtual European
Hematology Association Congress held on
June 9–17, 2021, and at the virtual 49th
Annual Sickle Cell Disease Association of
America, Inc. National Convention held on
October 12–16, 2021.

Conclusions: Based on its mechanism as an HbS polymerization inhibitor, voxelotor
improves Hb levels and markers of hemolysis and has the potential to mitigate SCDrelated complications; these results support its use in patients aged ≥4 years.
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1

INTRODUCTION

and adolescents aged ≥12 years under accelerated approval based on
increases in Hb.15 In February 2022, voxelotor was granted market-

Sickle cell disease (SCD) is an inherited hematological disorder caused

ing authorization in the European Union and United Arab Emirates for

by mutations in the HBB gene that encodes the beta-globin chain of

the treatment of SCD in adults and children ≥12 years of age.16 In

hemoglobin (Hb). SCD is more common among people of sub-Saharan

clinical studies and real-world practice, patients treated with voxelo-

African, Middle Eastern, Indian, and Mediterranean descent.1–3 Under

tor have shown improvements in Hb levels and reductions in hemolytic

conditions of deoxygenation, sickle hemoglobin (HbS) undergoes

markers.17–20 Accumulating real-world evidence also indicates that

rapid polymerization, causing red blood cell deformation, sickling, and

voxelotor may ameliorate complications of SCD, such as leg ulcers and

destruction, which in turn triggers a chronic cycle of hemolysis, anemia,

jaundice, as well as reduce transfusion dependence and the occurrence

and episodic vaso-occlusion.1 Repetitive ischemic injury and inflamma-

of vaso-occlusive crises (VOCs).19,21–25 Given the childhood manifes-

tion caused by anemia and hemolysis, beginning as early as 6 months of

tation pattern and progressive nature of SCD, treatment of pediatric

age in patients with SCD, lead to progressive end-organ damage, sub-

patients with disease-modifying agents such as voxelotor may provide

stantial morbidity, and early mortality.2,4 By age 6 years, approximately

clinical benefit if started at a young age.

25% of children with SCD have evidence of silent cerebral infarct, and

In this report, we present initial results from a cohort of 4- to

50% have had an episode of acute chest syndrome.5,6 Furthermore,

11-year-old patients with SCD under investigation in part C of the

onset of splenic and renal dysfunction at a young age increases the

four-part HOPE-KIDS 1 study, which is currently ongoing. These data

risk of premature death due to infection and chronic renal failure,

formed the basis for the FDA-accelerated approval of voxelotor in

respectively.7–10 Another serious complication, sickle cell retinopathy,

December 2021 for the treatment of SCD in children aged 4 to

which can potentially lead to blindness, is seen in 12.1% of children

11 years.26

with SCD.11 Despite the medical challenges faced by pediatric patients
with SCD, current treatment options remain limited, with hydroxyurea
(HU) being the sole disease-modifying therapy for many decades.

2

METHODS

Stem cell transplantation is available as a curative therapy, particularly
for those with severe phenotypes and unaffected, human leukocyte

2.1

Study design

antigen-matched siblings; however, stem cell transplantation has
its own concurrent risks, including engraftment failure, infertility,

The GBT440-007 (NCT02850406) phase 2a HOPE-KIDS 1 trial is

disease.12–14

a multicenter, four-part, open-label, single- and multiple-dose study

Transfusion therapy is also an important therapeutic option for man-

designed to evaluate the pharmacokinetics (PK), efficacy, and safety

agement of sickle cell-related anemia, but chronic transfusion poses

of voxelotor administered to pediatric patients with SCD. The four

substantial risks, including alloimmunization, iron overload, hemolysis,

parts of HOPE-KIDS 1, parts A to D, focus on different age groups

infection-related complications, and graft-versus-host

Gene therapy and gene editing are currently

and treatment regimens. Study parts A (single dose in patients aged 6–

being investigated as potential curative options, but these remain

17 years)27 and B (multiple doses in patients aged 12–17 years)27,28

experimental at this time.2 However, most patients with SCD can

are complete, and part D (multiple doses in patients aged 6 months

benefit from treatments that target the root cause of SCD pathol-

to <4 years)27 is currently enrolling patients. Part C of the study

and

hyperviscosity.12

ogy, HbS polymerization, which may alter the natural history of the

consists of a screening period (day −35 to day −1), a 48-week

disease.

treatment period, and an end-of-study visit 4 weeks after the last

In 2019, voxelotor, an oral, once-daily HbS polymerization inhibitor,

dose of voxelotor for patients who do not enroll into the open-label

was approved in the United States for the treatment of SCD in adults

extension study, GBT440-038 (NCT04188509) (Figure 1A). The PK,
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F I G U R E 1 Study design and trial profile. (A) Study design for part C of the GBT440-007 (HOPE-KIDS 1) study showing enrollment of study
patients as of September 30, 2020. (B) Consort diagram showing disposition of patients as of September 30, 2020. a End-of-study visit is 4 weeks
after the last dose for patients who will not enroll in the open-label extension study, GBT440-038. b One patient discontinued treatment at week
36 due to an adverse event but remained in the study for study assessments. c Twenty-one patients entered the open-label extension study

hematological response, and safety data as of September 30, 2020

2.2

Patients and treatment

from 45 patients aged 4 to 11 years, who received at least one dose
of voxelotor in part C of the study, were evaluated.

Patients with SCD were screened at 15 study sites in the United States,

This study was conducted in accordance with Good Clinical Prac-

Lebanon, and the United Kingdom. Key inclusion criteria included

tice guidelines and the ethical principles of the Declaration of Helsinki,

patients with SCD (homozygous SCD [HbSS] or HbSβ0 genotypes),

and was compliant with all applicable country-specific laws and

aged 4 to 11 years, and with Hb concentrations ≤10.5 g/dl at base-

regulations in the United States, Lebanon, and the United Kingdom.

line. Concomitant HU was allowed if the dose was stable for ≥3 months

The study protocol and all other appropriate study-related informa-

at enrollment, with no anticipated need for dose adjustment during

tion were reviewed and approved by institutional review boards and

the study. There was no eligibility requirement regarding prior VOCs.

independent ethics committees for each of the participating trial sites.

Patients who were receiving chronic red blood cell transfusion ther-

Written informed parental/guardian consent and patient assent, when

apy, had received a transfusion in the past 30 days, or had been hospi-

possible, were obtained prior to study.

talized for a VOC, acute chest syndrome, splenic sequestration crisis,
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TA B L E 1 Voxelotor weight-based dosing for pediatric patients
aged 4 to 11 years

TA B L E 2

Baseline characteristics of patients aged 4 to 11 years

Age group

4–11 years (N = 45)

Age at screening, median (range), years

7.0 (4–11)

600 mg

Female, n (%)

23 (51)

20 to <40 kg

900 mg

Weight at screening, median (range), kg

≥40 kg

1500 mg

Weight

Voxelotor dose

10 to <20 kg

Baseline Hb, g/dl

or dactylitis within 14 days before providing informed consent were

24 (12–41)

a

Mean (SD)

8.6 (1.0)

Range

6.1–10.5

Baseline reticulocyte count, %a

excluded.

Mean (SD)

All patients received dispersible voxelotor tablets, a pediatric formulation that can be dispersed in clear liquids, such as apple juice,

10.4 (4.5)

Range

2.1–19.5

soda, or water, for oral administration. Patients aged 4 to 11 years

Baseline HbF, %

received weight-based dosing of voxelotor administered once daily

Mean (SD)

17.7 (7.9)

Range

2.3–38.4

(Table 1). The weight-based dosing scheme for patients aged 11 years
and younger was developed using population PK and allometric scaling

a

SCD genotype, n (%)

and aimed to achieve comparable voxelotor exposure and similar Hb

HbSS

occupancy as the approved daily dose of 1500 mg voxelotor in patients

HbSβ

aged ≥12 years.

43 (96)

0

2 (4)

Current HU/hydroxycarbamide use, n (%)

Dose modification (reduction or interruption) of study drug was

Yes

recommended to manage tolerability issues related to voxelotor treatment. Temporary dose modification was permitted for management

38 (84)

No

7 (16)

of suspected drug-related adverse events. The original dose was

No VOCs in the previous 12 months, n (%)

21 (47)

resumed after resolution of the adverse event, at the discretion of the

≥1 VOC in the previous 12 months, n (%)

24 (53)

investigator.

2.3

Endpoints and assessments

Abbreviations: Hb, hemoglobin; HbF, fetal hemoglobin; HbSβ0 , sickle beta
zero thalassemia; HbSS, homozygous sickle cell disease; HU, hydroxyurea;
SCD, sickle cell disease; VOC, vaso-occlusive crisis.
a
Baseline is defined as the average of all values before the first dose.

Patients were assessed at the screening visit, day 1, and weeks 2, 4, 8,
12, 16, 20, 24, 36, and 48. Efficacy endpoints evaluated in the current
analyses included the percentage of patients who had an Hb response,
which was defined as an increase from baseline of >1.0 g/dl at week

3
3.1

RESULTS
Patients

24; the change in Hb level from baseline to week 24; and the percentage change in laboratory markers associated with hemolysis, including indirect bilirubin, reticulocytes, and lactate dehydrogenase (LDH),
from baseline to week 24. The safety assessment included treatment-

As of September 30, 2020, 45 patients aged 4 to 11 years were enrolled
in part C of the HOPE-KIDS 1 study. Among these patients, 27 had completed the study, of whom 21 rolled over to the open-label extension

emergent adverse events (TEAEs) and adverse events that led to treat-

study; 10 had discontinued early, and 8 were receiving ongoing treat-

ment modification or discontinuation.

ment. A summary of patient disposition is provided in Figure 1B. Base-

PK samples were collected post-dose on day 1 (a single sample

line demographics and clinical characteristics are shown in Table 2. At

between 15 minutes and 2 hours post-dose) and pre-dose (up to an

baseline, the mean (SD) Hb was 8.6 g/dl (1.0 g/dl), and the mean (SD)

hour prior to dosing) at weeks 4, 8, 12, 16, 20, 24, 36, and 48. PK analy-

reticulocyte count was 10.4% (4.5%), which closely matches with what

ses were performed to determine whole-blood and plasma PK param-

was previously reported for the phase 3 HOPE study that comprised

eters using a nonlinear mixed-effects modeling approach with NON-

mostly adult patients.18 Baseline mean (SD) fetal Hb percentage was

MEM, version 7.3.0 or higher (ICON Development Solutions, Elliot
City, MD, USA). PK parameters included minimum (Cmin ) and max-

17.7% (7.9%), consistent with 84% of patients receiving concomitant
HU at a stable dose.

imum (Cmax ) whole-blood or plasma concentration, area under the
concentration–time curve (AUC), terminal elimination half-life (t1/2 ),
and percentage Hb occupancy.

3.2

2.4

An increase in mean Hb levels was observed as early as 2 weeks after

Statistical analyses

Efficacy

voxelotor initiation and was maintained through week 24 (Figure 2A).
All efficacy and safety assessments were summarized with descriptive

The mean (SD) change in Hb from baseline at week 24 (n = 34)

statistics.

was 1.0 g/dl (1.2 g/dl). Of patients with Hb measurements at both

ESTEPP ET AL .
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F I G U R E 2 Changes in blood parameters from baseline. (A) Mean change in Hb from baseline at week 24. (B) Per patient change in Hb from
baseline at week 24. Each bar represents an individual patient. (C) Mean percentage change in hemolysis markers from baseline at week 24. Hb,
hemoglobin; LDH, lactate dehydrogenase
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TA B L E 3

PK parameters of voxelotor in patients aged 4 to 11 years in part C of the HOPE-KIDS 1 studya
4–11 years Voxelotor 600/900/1500 mgb (n = 38)

PK parameter
AUC0-24h (μg⋅h/mL)
Cmin (μg/mL)

c

c

Cmax (μg/mL)c
c

t1/2 (h)

Whole blood

Plasma

3257 (31.2)

221.8 (34.4)

117.8 (35)

7.7 (40)

148.3 (30.2)

10.3 (32.9)

27.2 (28.3)

% Hb occupancyc
% of patients with ≥20% Hb occupancy

26.2 (32.2)
d

76.3 (59.8–88.6)

Abbreviations: AUC0-24h , area under the concentration–time curve from 0 to 24 hours; BLQ, below the limit of quantification; Cmax , maximum whole-blood or
plasma concentration; Cmin , minimum whole-blood or plasma concentration; CI, confidence interval; CV, coefficient of variation; Hb, hemoglobin; PK, pharmacokinetics; t1/2 , terminal elimination half-life.
a
Estimates are based on 158 plasma observations and 173 whole-blood observations from day 1 to week 48; measurements that were BLQ or collected
outside of the prespecified post-dose timeframe were not included in the analysis.
b
Weight-based dosing for pediatric patients aged 4 to 11 years.
c
Geometric mean (%CV).
d
Percentage (95% exact CI).

baseline and week 24, 47% (n = 16/34; 95% CI: 30%–65%) achieved
an Hb response, defined for this study as an increase in Hb of >1.0 g/dl
from baseline to week 24 (Figure 2A). The Hb response for voxelotor
was 36% (n = 16/45) in patients who received at least one dose of voxelotor, regardless of whether they had an Hb measurement at week
24. At week 24, 35% (n = 12/34) and 21% (n = 7/34) of patients had a

TA B L E 4 Safety assessments at time of data cutoff date
(September 30, 2020)
Drug-related TEAEs (preferred term) reported for ≥2 patients
Adverse events,a n (%)

4–11 years (n = 45)

Any drug-related TEAE

22 (49)

Diarrhea

5 (11)

tively. Overall, 82% (n = 28/34) of patients had an increase in Hb of

Rashb

5 (11)

any magnitude from baseline at week 24 (Figure 2B). Additionally, con-

Vomiting

>1.5 g/dl increase and a >2.0 g/dl increase in Hb from baseline, respec-

5 (11)
c

current reductions in hemolytic markers were observed with voxelotor

Abdominal pain

therapy. The mean (range) percentage change from baseline at week

Transaminases increasedd

24 was –38.6% (–76.0% to 40.0%; n = 28) for indirect bilirubin, –3.3%

Headache

2 (4)

(–95.0% to 110.3%; n = 31) for reticulocyte count, and –2.6% (–36.6%

Hypersplenism

2 (4)

to 44.2%; n = 32) for LDH (Figure 2C).

Pyrexia

2 (4)

3.3

Pharmacokinetics

Voxelotor PK parameter estimates for whole blood and plasma are
summarized in Table 3. The half-life of voxelotor in children aged 4 to
11 years was 27.2 hours. The estimated mean Hb occupancy based on
Cmin was 26.2% in this population, with approximately 76% of patients
achieving an Hb occupancy >20%.

3.4

Safety

4 (9)
4 (9)

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CTCAE, Common Terminology Criteria for Adverse Events; MedDRA, Medical Dictionary for Regulatory Activities; NCI, National Cancer Institute; SCD, sickle cell disease; TEAE, treatment-emergent adverse
event.
a
TEAEs were coded using MedDRA version 23.0. NCI-CTCAE version 4.03
was used to determine grade. Patients may be counted in more than one
row.
b
Includes the following preferred terms: rash, rash maculopapular, and rash
papular.
c
Includes the following preferred terms: abdominal pain and abdominal pain
upper.
d
Includes the following preferred terms: ALT increased, AST increased, and
transaminases increased.

Safety analyses included all patients who received at least one dose
of the study drug (Table 4). As of the data cutoff date, the median

event assessed by the investigator as related to voxelotor. The most

exposure was 43.3 weeks. Weight-based dosing of voxelotor was well

common non-SCD-related TEAEs (reported in ≥10% of patients) were

tolerated in this patient population. Per the study protocol, a TEAE

pyrexia (36%), vomiting (33%), rash (20%), abdominal pain (18%), diar-

was defined as an adverse event occurring between the first dose

rhea (18%), headache (18%), viral infection (18%), pain in extremity

and 28 days after the last dose (inclusive) regardless of relationship

(16%), and upper respiratory tract infection (16%). The most commonly

to the study drug. A drug-related TEAE was defined as an adverse

reported drug-related TEAEs (reported in ≥10% of patients) were
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diarrhea (11%), rash (11%), and vomiting (11%); of these, most were

study population and the wide range of response observed among 4-

grade 1; grade 2 rash was reported in two instances, and no events of

to 11-year-old patients in the current analysis.

grade 3 or higher severity were observed. Only one temporary dose

The half-life of voxelotor in patients aged 4 to 11 years was

reduction occurred in one patient who had a drug-related TEAE of

27.2 hours, supporting once-daily dosing. The mean Hb occupancy

grade 2 rash that led to an initial dose interruption for 5 days, fol-

achieved with voxelotor weight-based dosing with dispersible tablets

lowed by a dose reduction for eight doses, and ultimately restoration

was 26%, which is within the target therapeutic range of 20% to 30%

of the original dose, with no further incidence of rash and subsequent

Hb occupancy. This target is based on the observation that individu-

patient enrollment into the open-label extension study. Three addi-

als who are compound heterozygous for HbS and a deletional form of

tional patients had temporary dose interruptions due to drug-related

hereditary persistence of fetal Hb and who maintain a pancellular fetal

TEAEs: one patient with a grade 2 hypersensitivity, one patient with

Hb distribution of 20% to 30%, generally exhibit a very mild clinical

a grade 2 alanine aminotransferase increase and a grade 2 aspartate

phenotype of SCD.30

aminotransferase increase, and one patient with a grade 3 bilirubin

The safety profile of voxelotor in patients 4 to 11 years of age

increase and a grade 3 liver transaminase increase. In both patients

was consistent with the existing safety profile in adult and adolescent

with elevated liver enzyme TEAEs, the events resolved after the tem-

(aged ≥12 years) patients. The most common non-SCD-related TEAEs

porary dose interruption with no further incidence, and both patients

(reported in ≥10% of patients) were pyrexia, vomiting, rash, abdominal

enrolled into the open-label extension study for continued voxelotor

pain, diarrhea, headache, viral infection, pain in extremity, and upper

dosing. The patient with a temporary dose interruption due to a grade

respiratory tract infection. Temporary dose modifications were infre-

2 hypersensitivity initially recovered but then discontinued voxelotor

quent and were used to manage TEAEs. This likely contributed to the

due to multiple drug-related adverse events of grade 2 allergic edema,

low rate of drug discontinuation due to TEAEs observed in this study.

grade 2 pyrexia, and grade 2 sickle cell anemia with crisis. Nonethe-

No new safety signals were identified.

less, overall drug discontinuation due to TEAEs was low. A total of 11

Patients in the study received weight-based dosing of voxelotor in

patients discontinued voxelotor early, and a breakdown of these dis-

a dispersible tablet-based pediatric formulation. This requires disper-

continuations are listed in Figure 1B. There were no deaths reported.

sion of 300-mg tablets, of a variable number depending on the patient’s
weight, in room temperature water or some other clear drink, such
as apple juice or soda, immediately before administration. Contents

4

DISCUSSION

are swirled to mix thoroughly prior to oral consumption. Tablets are
expected to disperse but not fully dissolve, and any leftover residue

The HOPE-KIDS 1 study is the first trial investigating the PK, efficacy,

should be resuspended in additional liquid and administered. Given

and safety of voxelotor treatment in patients aged 4 to 11 years with

the novel texture and taste of this suspension, patients were encour-

SCD. These initial results from part C of the trial show that the efficacy

aged to dissolve tablets in their favorite clear beverage and/or to keep

of voxelotor in patients with SCD aged 4 to 11 years is consistent

a favorite beverage available for consumption immediately after drug

with that observed in adult and adolescent (aged ≥12 years) patients

administration.

in the phase 3 HOPE trial.18 Hb response (defined in this study as

Despite the risk of serious and potentially life-threatening com-

>1.0 g/dl increase from baseline) was achieved by 55% (n = 24/44) of

plications in young children with SCD, current treatment options for

patients as early as week 2 and maintained through week 24 in 47%

pediatric patients are lacking. While transfusion therapy represents an

(n = 16/34) of patients who had Hb measurements at baseline and

effective way to manage both acute and chronic comorbid complica-

week 24. In addition, 35% and 21% of patients achieved Hb increases

tions of SCD (such as stroke, acute chest syndrome, and multisystem

>1.5 g/dl and >2.0 g/dl, respectively. Overall, 82% patients had an

organ failure), the safe implementation of chronic transfusion therapy

increase in Hb from baseline at week 24. The mean increase in Hb from

requires careful monitoring for potentially severe side effects, includ-

baseline at week 24 was 1.0 g/dl. Furthermore, at week 24, concurrent

ing alloimmunization, iron overload, hemolysis, and hyperviscosity.12 In

improvements in hemolytic markers were also observed. These results

infants older than 9 months of age, children, and adolescents with sickle

are comparable to findings from the phase 3 HOPE trial and emerging

cell anemia, the 2014 National Institutes of Health guidelines recom-

evidence from real-word analyses.18,20,25,29 In the HOPE study, 51% of

mend treatment with HU regardless of clinical severity to reduce SCD-

adult and adolescent (aged ≥12 years) patients treated with voxelotor

related complications such as pain, dactylitis, acute chest syndrome,

1500 mg demonstrated a Hb response, and the mean change in Hb

and anemia.12 For children aged 2 to 16 years with SCD, the 2020

from baseline at week 24 was 1.1

g/dl.18

Additionally, the percentage

American Society of Hematology guidelines suggest HU treatment

changes in indirect bilirubin and LDH at week 24 in the HOPE study

for patients with abnormal transcranial Doppler results (≥200 cm/s

(–29.1%, n = 67, and –4.5%, n = 72, respectively) were similar to

time-averaged mean of maximum velocity) who have been receiving

changes observed in this analysis (–38.6%, n = 28, and –2.6%, n = 32,

transfusion therapy for primary stroke prevention for ≥1 year, have

respectively). The percentage change in reticulocyte count at week

magnetic resonance imaging/magnetic resonance angiography findings

24 was greater in the HOPE study (–19.9%, range: –29.0% to –10.9%;

that exclude silent cerebral infarcts and cerebral vasculopathy, and are

n = 71) compared with that in this analysis (–3.3%, range: –95.0% to

interested in stopping transfusion therapy.31 However, despite the use

110.3%; n =

of HU in the majority of pediatric patients (84%) and a mean fetal Hb

31).18

This variation could be reflective of the smaller
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level of 17.7% at baseline in this analysis, there was substantial evi-
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patients with SCD should be a research priority.

peutics, Bluebird Bio, Forma Therapeutics; research funding: Novartis

such therapies currently

Voxelotor is the only approved therapy for the treatment of SCD

Pharmaceuticals, Global Blood Therapeutics, Forma Therapeutics,

in adult and pediatric patients aged ≥4 years that targets the primary

Bluebird Bio. Connie Piccone: Speaker: Novartis Pharmaceuticals,

trigger of SCD pathology: HbS polymerization.15 HbS polymerization

Global Blood Therapeutics. Miguel R. Abboud: Consultant: Novartis

and red blood cell sickling underlie the serious and life-threatening

Pharmaceuticals, Novo Nordisk; research funding: Global Blood Ther-

clinical complications of SCD.2,36 Voxelotor has been shown to disrupt

apeutics, Eli Lilly, Modus Pharmaceuticals, AstraZeneca; honoraria:

the relentless cycle of sickling and to improve key measures of red

Novartis Pharmaceuticals, Global Blood Therapeutics; advisory board:

blood cell health (improved RBC deformability), which can translate

AstraZeneca, Global Blood Therapeutics, Crispr Therapeutics. Kim

to reduced hemolysis, improvements in anemia, and increased ability

Smith-Whitley: Employee, stockholder: Global Blood Therapeutics.

of blood to deliver oxygen to tissues.1,17,37–40 Furthermore, mounting

Sandra Dixon: Employee, stockholder: Global Blood Therapeutics.

real-world evidence suggests that voxelotor may ameliorate SCD com-

Margaret Tonda: Employee, stockholder: Global Blood Therapeutics.

plications (e.g., leg ulcers and jaundice) and reduce transfusion depen-

Carla Washington: Clinical consultant, shareholder: Global Blood

dence and the occurrence of VOCs.19,21–25 Due to its mechanism of

Therapeutics. Noelle M. Griffin: Employee, stockholder: Global Blood

action, voxelotor has the potential to alter disease pathogenesis and

Therapeutics. Clark Brown: Consultant, research support: Global

mitigate disease-associated morbidity and mortality, especially when

Blood Therapeutics; consultant: Imara, Novo Nordisk; research

used as an early intervention for pediatric patients.

support: Novartis Pharmaceuticals, Pfizer, Imara, Forma Therapeutics.

The analysis presented here has some limitations. It is subject to the
biases associated with an open-label study design, and the data are in
a limited number of patients. Nonetheless, these findings provide evidence that the efficacy and safety profile of voxelotor in patients aged
4 to 11 years are consistent with the existing profiles in adult and adolescent (aged ≥12 years) patients. These data also support the therapeutic efficacy of weight-based dosing in children aged 4 to 11 years.
Overall, these data support the use of voxelotor in pediatric patients
aged 4 years and older with SCD as a strategy to target the disease at an
early stage and impede or prevent disease sequelae. The effect of voxelotor on cerebral hemodynamics in pediatric patients with SCD is currently being investigated in the HOPE-KIDS 2 (NCT04218084) trial.
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